L
Lavie bio
Innovative company promoting food quality and agricultural sustainability through the introduction of microbiome based ag-biological products
About Lavie bio
Lavie Bio is a pioneering company in the agricultural biotechnology sector, focusing on improving food quality, agricultural sustainability, and productivity through microbiome-based biological products. These products are derived from naturally occurring microbial populations that live close to or within plants. Lavie Bio serves farmers and agricultural businesses, aiming to enhance crop yields, reduce chemical residues, and promote environmentally friendly farming practices.
Read full description
The company operates in the global agricultural market, leveraging advanced informatic technologies and proprietary algorithms to analyze and design its products. Lavie Bio's business model revolves around the discovery, optimization, and development of bio-stimulants and other agricultural solutions. These products are designed to improve pest management, stimulate plant growth, and optimize input utilization, ultimately driving yield per acre.
Lavie Bio generates revenue through the commercialization of its bio-stimulants and other ag biological products, which are in various stages of development and pre-commercialization. The company’s data-driven approach, utilizing a vast interconnected BIG DATA hub, allows for continuous improvement and validation of its products.
At a glance
- Status
- Acquired
- Founded
- 2019
- Headquarters
- Rehovot, Israel
- Employees
- 42
- Open positions
- None listed
- Dealroom signal
- 40.7/100
- Sub-industry
- AgriTech, Innovative Food
- Sector
- eCommerce & Marketplaces, Biotechnology, Crop Protection, Pest Control, Biopesticides, Pesticides, Sustainable Development Goals, Biotechnology in Food, Climate Tech, Hard Tech
- Business model
- Manufacturing, Marketplace & ecommerce
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning Lavie bio.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITION✓Exit | Apr 2025 | $0 | — | ICL | ↗ |
| GRANT✓Other financing | Sep 2024 | $0 | — | The Israel Innovation Authority | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Lavie bio is 920 monthly website visits, up 1.1% over the last three months. Lavie bio's team grew 10.5% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
The Israel Innovation Authority
Series A1 investor entered at this stage
ICL
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Lavie bio on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Lavie bio’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.